Colorado Springs News, Sports & Business

Gazette Premium Content Spectranetics set for largest acquisition in company history

photo - Spectranetics CEO Scott Drake poses in this 2011 file photo. The company is poised to purchase AngioScore Inc., in what will be Spectranetics' largest acquisition ever.    (The Gazette, Christian Murdock) + caption
Spectranetics CEO Scott Drake poses in this 2011 file photo. The company is poised to purchase AngioScore Inc., in what will be Spectranetics' largest acquisition ever. (The Gazette, Christian Murdock)
by WAYNE HEILMAN wayneh@gazette.com - Updated: May 27, 2014 at 4:32 pm

Spectranetics Corp. announced Tuesday the Colorado Springs-based medical laser manufacturer will next month acquire a California company that manufactures angioplasty balloons in a $230 million deal that is the biggest acquisition in its 30-year history.

Spectranetics will acquire Fremont, Calif.-based AngioScore Inc., a privately held firm that develops, manufactures and sells cardiovascular specialty balloons, in a deal evenly split between cash and stock, though the company said it plans to finance the entire purchase price by issuing $200 million Wednesday in 20-year bonds that could be converted into stock. The transaction is expected to be completed by June 30, when AngioScore will become a subsidiary of Spectranetics.

"The attractiveness of this deal compelled us to act," Spectranetics CEO Scott Drake said in a conference call Tuesday with stock analysts, investors and others. "This combination makes perfect sense in terms of strategic fit, technology, scale and reach."

AngioScore was started in 2003 by a California cardiologist and a veteran of the medical device industry and generated $55 million in revenue last year, growing at an annual rate of 14 percent during the past three years and 20 percent last year. The company employs 170.

The combined company had revenue totaling $213.5 million and generated operating earnings of $10.1 million. Spectranetics said in a press release announcing the deal that it expects the acquisition to add to operating earnings next year and save up to $10 million in annual operating costs.

"Simply put, we are 'better together,'" AngioScore CEO Thomas Trotter said the release. "We believe that this combination provides an opprotunity to build a remarkable future while delivering life-impacting technologies to physicians and patients."

Comment Policy

Our commenting system has changed. Please register or login with your gazette.com account to comment on a story. Click here for information.

You've reached your 4 FREE premium stories this month

Get 4 more FREE stories

Simply register to continue.

Register

Subscribe now

Get access unlimited access to premium stories.

Subscribe
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
OCT
21
OCT
22
OCT
23
OCT
24
OCT
25
OCT
26
OCT
27
OCT
28
OCT
29
OCT
30
OCT
31
NOV
1
NOV
2
NOV
3
Advertisement